{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Afya Ltd. overvalued or undervalued?
As of July 7, 2025, Afya Ltd. is considered undervalued with a valuation grade upgrade to attractive, supported by favorable P/E, PEG, and EV to EBITDA ratios, despite mixed stock performance showing a 1-year return of -2.86% compared to the S&P 500's 17.14%, and a 3-year return of 14.24% versus the S&P 500's 70.41%.
Afya Ltd. Faces Bearish Technical Trends Despite Strong Management Efficiency and Growth
Afya Ltd., a microcap in the Tour and Travel Related Services sector, has experienced a score adjustment due to changes in technical trends, now reflecting bearish signals. Despite this, the company showcases strong management efficiency, low debt levels, and healthy long-term growth, with no significant negative triggers affecting its performance.
Is Afya Ltd. overvalued or undervalued?
As of October 5, 2023, Afya Ltd. is considered undervalued with a favorable valuation outlook, featuring a P/E ratio of 15.2 and a P/B ratio of 3.1, outperforming peers like Dasa Holdings and Health Catalyst.
Is Afya Ltd. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data for Afya Ltd. to determine if it is bullish or bearish.
What does Afya Ltd. do?
Afya Ltd. is a Brazil-based medical education group focused on providing a physician-centric ecosystem for lifelong medical learners. As of March 2025, it reported net sales of $160 million and a net profit of $44 million, with a market cap of approximately $1.73 billion.
How big is Afya Ltd.?
As of Jun 18, Afya Ltd. has a market capitalization of 1,733.87 million, with net sales of 612.60 million and net profit of 123.88 million over the latest four quarters. Shareholder's funds are 691.17 million and total assets are 1,429.23 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
